Subtype switch between pri rimary and recurrent breast cancer Su ing - - PowerPoint PPT Presentation
Subtype switch between pri rimary and recurrent breast cancer Su ing molec ism and th the underly th lyin lecula lar r mechanis therapeutic ic im impli licatio ions Supervisors: Dr. Maya Dadiani Dr. Einav Gal Yam Breast cancer
Supervisors: Dr. Maya Dadiani Dr. Einav Gal Yam Breast cancer translational research Student: Inbar Eisenkot
Nature, Outlook Breast Cancer 2012
Nature, Outlook Breast Cancer 2012
Huge international efforts to profile Breast Cancer TCGA > 2800 tumors METABRIC > 2500 tumors Metastatic BC > 300 tumors
TCGA, Nature 490, 61–70, 2012
gene expression pathways and regulators
Progesterone receptor (PR) Estrogen receptor (ER) human epidermal growth factor type 2 (HER2)
Sorlie Perou, PNAS, 2001
Does a switch in ER/PR expression dictate a dramatic reprogramming of the molecular signatures? Subtype switch usually leads to a change in the subsequent treatment plan
The only remaining option is usually chemotherapy
1st Aim clinical and pathological characteristics of subtype switch database and clinical records analysis 2nd Aim MOLECULAR PROFILING OF MATCHED CASES Primary Recurrence
n=2241 Patients in DB n=220 Primary: Hormone Positive n=182 Stable HR positive Matched samples n=38 HR Positive to HR negative patients N=647 Patients with recurrence n=68 Stable Hormonal Negative patients
ER TN subtype switch rate in our cohort is 13% which aligns with the literature
N=288 Patients with known recurrence subtype status
Clinical parameter ER TN ER ER TN TN ER percentage ER intensity PR percentage PR intensity HER2 Age Stage Lymph nodes Grade KI 67 Recurrence location Surgery type Chemotherapy Endocrine treatment RFS OS
P-value= 1.2x10−5
ER positive cells
Primary tumor Recurrent metastasis Region 1: ER+++ Region 2: ER-
HER
הלחמ תרזח תעב םהלש גוויסה תא םינשמ םילודיגהמתיתרורג
תוצובקה ןיב םינוש
לודיגל המוד םהמ הזיאו םינוש םירוזא רפסמ םנשייתרורגה?